Ringworm Treatment Market Led by South Korea as Bayer AG and Novartis Strengthen Antifungal Treatment Portfolios

According to the latest market analysis by Future Market Insights, the global ringworm treatment market is witnessing steady growth supported by the high prevalence of dermatophyte infections, expanding over-the-counter (OTC) antifungal availability, rising consumer awareness regarding fungal skin diseases, and growing adoption of effective topical and oral antifungal therapies.

Market analysis indicates the ringworm treatment market was valued at USD 9.27 billion in 2025 and is projected to reach approximately USD 9.7 billion by 2026-end before expanding to USD 15.53 billion by 2036, reflecting a CAGR of 4.8% during the 2026-2036 forecast period.

The market is projected to create an incremental opportunity of approximately USD 5.81 billion between 2026 and 2036, supported by increasing treatment-seeking behavior, expanding pharmacy access, growing self-medication trends, and continued innovation in antifungal formulations.

Quick Stats: Ringworm Treatment Market

• Market Value (2025): USD 9.27 Billion
• Estimated Market Size (2026): USD 9.7 Billion
• Forecast Market Value (2036): USD 15.53 Billion
• CAGR (2026-2036): 4.8%
• Incremental Opportunity (2026-2036): USD 5.81 Billion
• Leading Drug Class Segment (2026): Antifungals - 48.9% Share
• Leading Route of Administration Segment (2026): Topical - 63.7% Share
• Leading Infection Type Segment (2026): Tinea Corporis - 33.6% Share
• Fastest Growing Markets: South Korea (5.4%) and Japan (5.3%)

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-16468

Growing Prevalence of Dermatophyte Infections Continues to Drive Market
Growth

The increasing incidence of fungal skin infections across both developed and emerging economies remains a major factor supporting growth in the ringworm treatment market. Urbanization, growing participation in sports activities, communal facility usage, and warm, humid climates continue to contribute to rising infection rates globally.

Healthcare providers and consumers increasingly prioritize early diagnosis and treatment to prevent recurrence, transmission, and complications associated with untreated fungal infections.

OTC Antifungal Products Strengthen Long-Term Demand

Growing availability of OTC antifungal creams, sprays, powders, and lotions continues generating opportunities across the ringworm treatment landscape.

Modern treatment solutions help:

• Improve patient convenience and compliance
• Support self-treatment of mild infections
• Reduce healthcare visits for uncomplicated cases
• Expand access through retail pharmacy channels
• Deliver effective symptom management

Product Innovation Creates New Opportunities Across Fungal Infection
Management

Continuous innovation in antifungal formulations, improved topical delivery systems, combination therapies, and consumer-friendly application formats is creating new growth opportunities across the market.

Healthcare providers increasingly prioritize suppliers capable of offering:

• Broad-spectrum antifungal efficacy
• Convenient treatment regimens
• Improved patient adherence
• Enhanced safety profiles
• Cost-effective treatment options

Antifungals Maintain Leading Drug Class Position

Antifungals are expected to remain the leading drug class segment in 2026, accounting for approximately 48.9% of the global market share.

Demand remains strong due to:

• Proven clinical effectiveness
• Broad availability across OTC and prescription channels
• Strong physician and consumer familiarity
• Effectiveness against multiple dermatophyte species

Topical Treatments Lead Route of Administration Adoption

Topical treatments are projected to account for approximately 63.7% of the route of administration segment in 2026, supported by ease of use, localized treatment effectiveness, affordability, and wide OTC availability.

Growing adoption across pharmacies, dermatology clinics, and homecare settings continues supporting segment growth globally.

Regional Outlook: South Korea Leads Global Market Expansion

South Korea
South Korea continues demonstrating strong market growth supported by accessible dermatology services, increasing consumer awareness regarding fungal infections, and expanding availability of OTC antifungal products.
The country is projected to expand at a CAGR of 5.4% through 2036.

Japan
Japan continues witnessing healthy market growth supported by strong skin health awareness, extensive pharmacy networks, and continued innovation in antifungal treatment products.
The country is projected to expand at a CAGR of 5.3% through 2036.

United States
The United States continues maintaining strong market growth supported by high OTC antifungal sales, increasing awareness of fungal skin conditions, and strong dermatology treatment infrastructure.
The country is projected to expand at a CAGR of 5.2% through 2036.

European Union
The European Union continues experiencing stable market growth supported by harmonized pharmaceutical regulations, established pharmacy networks, and growing consumer healthcare awareness.
The region is projected to expand at a CAGR of 5.1% through 2036.

United Kingdom
The United Kingdom continues witnessing consistent market growth supported by NHS dermatology services, pharmacy-led care programs, and increasing consumer self-care trends.
The country is projected to expand at a CAGR of 4.8% through 2036.

Customize insights for your business strategy: https://www.futuremarketinsights.com/customization-available/rep-gb-16468

Competitive Landscape Focuses on Brand Strength and Antifungal Innovation

The ringworm treatment market remains highly competitive, with major companies focusing on expanding antifungal portfolios, strengthening retail distribution networks, enhancing consumer awareness, and developing improved treatment formulations to reinforce market positioning.

Key Industry Participants Include:

• Bayer AG
• Novartis AG
• GlaxoSmithKline plc
• Perrigo Company plc
• Johnson & Johnson
• Glenmark Pharmaceuticals
• Cipla Ltd.

Outlook Through 2036

The ringworm treatment market is expected to maintain steady long-term growth as healthcare providers, pharmacies, and consumers increasingly prioritize effective fungal infection management and accessible treatment solutions.

Future market growth is expected to be supported by:

• Rising global prevalence of dermatophyte infections
• Expansion of OTC antifungal product availability
• Growing awareness of fungal skin health
• Increasing demand for convenient topical therapies
• Advancements in antifungal formulations
• Strengthening retail pharmacy distribution networks

Explore In-Depth Healthcare Market Insights: https://www.futuremarketinsights.com/industry-analysis/healthcare

Explore Industry Insights: https://www.futuremarketinsights.com/industry-analysis

Purchase Full Report for Detailed Insights: https://www.futuremarketinsights.com/reports/ringworm-treatment-market

Why FMI: https://www.futuremarketinsights.com/why-fmi

Explore More Related Studies Published by FMI Research:

Palliative Care Market: https://www.futuremarketinsights.com/reports/palliative-care-market

Behavioral Health Market: https://www.futuremarketinsights.com/reports/behavioral-health-market

Chromatography Resin Market: https://www.futuremarketinsights.com/reports/chromatography-resin-market

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

This release was published on openPR.